This is a prospective, multicenter study intended to provide supportive clinical information on the use of the SAPH device to achieve radial artery patent hemostasis after a transradial procedure.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Efficacy Endpoint - Percent of subjects with radial artery hemostasis with patency at time of discharge
Timeframe: 60 minutes prior to same-day discharge or within 24 hours post-TRA procedure.
Safety Endpoints - 1) Percentage of subjects with radial artery patency 2) No major device-related access site-related complications prior to discharge
Timeframe: 60 minutes prior to same-day discharge or within 24 hours post-TRA procedure